Check Credit Score
Check Credit Score
HomeNewsWorld

Coronavirus pandemic | Sanofi, GSK come together to develop vaccine for COVID-19

As per the partnership, France-based Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology.

April 15, 2020 / 10:27 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Pharma majors Sanofi and GSK on Tuesday said they have joined hands to develop a vaccine for COVID-19. The companies in a joint statement said they have signed a letter of intent to develop an adjuvanted vaccine for COVID-19, using innovative technology from both firms, to help address the ongoing pandemic.

As per the partnership, France-based Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology.

The technology has produced an exact genetic match to proteins found on the surface of the virus and is the basis of Sanofi's licensed recombinant influenza product in the US.

COVID-19 pandemic LIVE updates

London-headquartered GSK, on the other hand, will contribute its proven pandemic adjuvant technology.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.

"As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone," Sanofi CEO Paul Hudson said.

That is why Sanofi is continuing to complement its expertise and resources with peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus, he added.

"By combining our scientific expertise, technologies and capabilities, we believe that we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19," GSK CEO Emma Walmsley said.

The companies plan to initiate phase one clinical trials in the second half of 2020 and, if successful, subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.

The entities have set up a joint task force, co-chaired by David Loew, Global Head of Vaccines, Sanofi and Roger Connor, President Vaccines, GSK.

The task force will seek to mobilise resources from both companies to look for every opportunity to accelerate the development of the candidate vaccine.

Follow our full coverage of the coronavirus pandemic here.

PTI
first published: Apr 15, 2020 10:22 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347